New imaging agent could spot hidden breast cancer spread
NCT ID NCT04758780
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new radioactive tracer called 89Zr-TLX250 for PET scans in 12 people with metastatic triple negative breast cancer. The goal was to see if it could find more tumors than the standard FDG PET scan, especially in the brain. Researchers compared the number of lesions detected by each scan to see if the new tracer is more sensitive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
89Zr-TLX250 (a radioactive tracer for PET scans)
What this could lead to
If successful, this could lead to a more accurate imaging method for detecting metastatic triple negative breast cancer, especially in the brain.
What could go wrong
This is a small, early-phase study with only 12 participants, so results may not apply to everyone. The new tracer may not prove better than existing scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICO René Gauducheau
Saint-Herblain, 44805, France